Drug Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Drug Name SGN-LIV1A
Trade Name Ladiratuzumab vedotin
Drug Descriptions

Ladiratuzumab vedotin (SGN-LIV1A) is a conjugate of anti-zinc transporter LIV-1 antibody and monomethyl auristatin E (MMAE), which delivers the cytotoxic agent to LIV1-positive cells, resulting in antitumor activity (PMID: 25253783).



  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Therapy Name Drugs Efficacy Evidence Clinical Trials
Atezolizumab + SGN-LIV1A Atezolizumab SGN-LIV1A 0 1
Pembrolizumab + SGN-LIV1A Pembrolizumab SGN-LIV1A 0 1
SGN-LIV1A + Trastuzumab SGN-LIV1A Trastuzumab 0 1

Additional content available in CKB BOOST